FAKTOR OPTIONSSCHEIN - GILEAD SCIENCES | Market Closed - Deutsche Boerse AG 18:26:35 31/05/2024 BST | ||
| 8.65 EUR | +4.85% |
|
| Current month | +6.40% | ||
| 1 month | +6.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 8.65 | +4.85% |
| 30/05/24 | 8.25 | -6.25% |
| 29/05/24 | 8.8 | +4.14% |
| 28/05/24 | 8.45 | +12.82% |
| 27/05/24 | 7.49 | -3.97% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 06:26 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | UBS |
| WKN | UL68TU |
| ISIN | DE000UL68TU5 |
| Date issued | 09/08/2023 |
| Strike | 80.1 $ |
| Maturity | Unlimited |
| Parity | 1.74 : 1 |
| Emission price | 4.98 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.15 € |
|---|---|
| Lowest since issue | 2.95 € |
| Spread | 0.3 € |
| Spread % | 3.46% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.27
USD
Average target price
82.7
USD
Spread / Average Target
+28.67%
- Stock Market
- Certificates
- Certificat
